Cargando…
Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
BACKGROUND: Risk factors for and optimal surveillance of renal dysfunction in patients on tenofovir disoproxil fumarate (TDF) remain unclear. We investigated whether a urine protein-osmolality (P/O) ratio would be associated with renal dysfunction in HIV-infected persons on TDF. METHODS: This retros...
Autores principales: | Marcelin, Jasmine R., Berg, Melody L., Tan, Eugene M., Amer, Hatem, Cummins, Nathan W., Rizza, Stacey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752319/ https://www.ncbi.nlm.nih.gov/pubmed/26872144 http://dx.doi.org/10.1371/journal.pone.0149562 |
Ejemplares similares
-
1571 Risk factors for Tenofovir-associated Renal Dysfunction in HIV-positive Patients
por: Marcelin, Jasmine Riviere, et al.
Publicado: (2014) -
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020) -
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015) -
Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)